Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Cardiotoxicity
研究概览
简要总结
This research study is evaluating the use of Cardiac Magnetic Resonance Imaging (CMR) as a method of detecting early signs of damage to the heart that can be associated with anthracycline-based chemotherapy for the treatment of breast cancer.
详细描述
One of the side effects observed in breast cancer patients receiving anthracycline-based treatment is heart complications in which the heart muscle is weakened and no longer able to pump sufficient amounts of blood throughout the body. This complication can lead to the following symptoms: shortness of breath on exertion, swollen ankles and feet, lack of energy and a reduced capacity to carry out day-to-day activities.
This research study is focused on identifying the early signs of such heart complications using CMR, which may allow preventative treatment options to be made available in future.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age > 18 years
- •Have histologic diagnosis of breast carcinoma
- •Scheduled to receive standard clinical therapy designed by their treating oncologist
- •Patients should receive anthracycline as part of the recommended treatment
- •Able to give informed consent.
排除标准
- •Contraindication to contrast CMR including eGFR <30 mls/min/1.73m2
- •Uncontrolled serious concurrent illness
- •Pregnancy or breast feeding
结局指标
主要结局
Cardiotoxicity
时间窗: 1 year after completion of treatment
Cardiotoxicity as measured by changes in left ventricular ejection fraction within one-year of completion of treatment
次要结局
未报告次要终点
研究者
Reza Nezafat
Principal Investigator
Beth Israel Deaconess Medical Center